InvestorsHub Logo

biotech_researcher

07/31/15 1:43 PM

#193983 RE: DewDiligence #193980

That just might explain it.. Thanks Dew!

jbog

07/31/15 4:25 PM

#193990 RE: DewDiligence #193980

They had originally stated that it was a multi-year agreement so this shouldn't be a surprise.

Has Abbvie ever stated the volume or size of the Express Scripts deal?

TIA

justrpaul

07/31/15 4:29 PM

#193991 RE: DewDiligence #193980

When the ABBVIE/ESRX deal was announced last December, ESRX said they would now treat all HCV sufferers regardless of disease severity. If we use an average commercial prevalence rate, ESRX's 25 million member national plan has about 125,000 members with HCV, of those maybe 88,000 are GT1. Given the continuing small viekira numbers, one has to doubt the ESRX promise of treating everyone without regard to disease severity.